AQST
Aquestive Therapeutics, Inc.
AQST offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR
Oscar Health, Inc.
OSCR has the edge over AQST overall, supported by stronger fundamentals and lower modeled downside.
AQST Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Unavailable |
AQST's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
AQST PE Valuation
AQST has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
AQST Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect AQST's revenue to grow and its profitability to improve, with its earnings holding steady. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over AQST on the outlook, with more favorable earnings expectations.
AQST Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.64 | +$0.06 |
| Q2 2026 | -$0.65 | +$0.04 |
| Q1 2026 | -$0.61 | -$0.03 |
| Q4 2025 | -$0.78 | -$0.27 |
| Q3 2025 | -$0.70 | -$0.26 |
| Q2 2025 | -$0.69 | -$0.35 |
| Q1 2025 | -$0.58 | -$0.17 |
| Q4 2024 | -$0.51 | -$0.38 |
AQST is still losing money, but far less than before: $0.64 per share over the past year, against $2.63 at its worst in late 2019.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over AQST on earnings quality, reporting a profit while its opponent remains loss making.
AQST Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.6M | -41% |
| Q2 2026 | $13.8M | +38% |
| Q1 2026 | $14.4M | +66% |
| Q4 2025 | $13M | +9.7% |
| Q3 2025 | $12.8M | -5.4% |
| Q2 2025 | $10M | -50% |
| Q1 2025 | $8.7M | -28% |
| Q4 2024 | $11.9M | -10% |
AQST's revenue is growing: $8M last quarter, down 41% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -191% | -102 points |
| Q2 2026 | -60% | +54 points |
| Q1 2026 | -29% | +193 points |
| Q4 2025 | -222% | -107 points |
| Q3 2025 | -90% | -28 points |
| Q2 2025 | -114% | -114 points |
| Q1 2025 | -222% | -148 points |
| Q4 2024 | -114% | -85 points |
AQST's operating margin was −191% last quarter, down 102 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over AQST on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over AQST on profitability, with a higher operating margin.
AQST Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$7.6M | +$5.3M |
| Q2 2026 | -$9.7M | -$1.6M |
| Q1 2026 | -$14.9M | +$8.7M |
| Q4 2025 | -$8.6M | -$2.1M |
| Q3 2025 | -$12.9M | -$924K |
| Q2 2025 | -$8M | -$980K |
| Q1 2025 | -$23.5M | -$13.1M |
| Q4 2024 | -$6.5M | -$1.5M |
AQST has burned cash in almost every quarter: −$41M over the past year, against −$51M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over AQST on cash generation, producing positive trailing cash flow while its opponent burns cash.
AQST Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +555K shares |
| 1 year | +14% | +15M shares |
| 3 years | +94% | +60.9M shares |
| 5 years | +220% | +86.3M shares |
| Available history | +274% | +92M shares |
AQST has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
AQST Net Leverage
AQST's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
AQST Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.3 | Neutral |
| Stochastic | 9.9 | Oversold |
AQST's weekly RSI is 40 (neutral) and its Stochastic is 10 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
AQST PE vs Healthcare Sector
AQST has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
AQST Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.11 | 13% below |
| 20 week MA | $4.26 | 16% below |
| 50 week MA | $4.32 | 17% below |
| 100 week MA | $4.14 | 14% below |
| 200 week MA | $3.42 | 4.4% above |
AQST has fallen below most of its moving averages, though it's still 4.4% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over AQST on trend strength, trading above more of its moving averages.
AQST Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.54 | $6.37 | +15% |
| 2021 | $6.37 | $4.03 | -37% |
| 2022 | $4.03 | $0.93 | -77% |
| 2023 | $0.93 | $2.02 | +117% |
| 2024 | $2.02 | $3.52 | +74% |
| 2025 | $3.52 | $5.99 | +70% |
| 2026 YTD | $5.99 | $3.57 | -40% |
AQST's yearly returns have swung widely, from +117% in 2023 to −77% in 2022. It's down 40% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over AQST on returns for 2026, with the stronger performance.